ASTERIX version 1
Research type
Research Study
Full title
ASTERIX: Adaptive Stratification of COVID19 to facilitate Endotype-directed Intervention Studies
IRAS ID
283989
Contact name
Kevin Blyth
Contact email
Sponsor organisation
R&I, NHS Greater Glasgow and Clyde, Glasgow
Clinicaltrials.gov Identifier
To be confirmed, ISRCTN; 20/WS/0077, REC Reference
Duration of Study in the UK
1 years, 0 months, days
Research summary
Research Summary:
The new coronavirus19 disease is a rapidly emerging global health threat and, as yet, does not have effective therapies for severe disease. The disease can affect people very differently and we wish to look at subtypes using biological signatures to help us design clinical trials that have the highest chance of success. ASTERIX is an observational study that will collect surplus samples (blood, respiratory secretions and urine) and data on COVID patients admitted to hospital. Models will be produced that identify patients at the highest risk of adverse outcomes and how these might be addressed in future trials that our group plan to design.Lay Summary of results:
The data is currently being analysed for the cohort of 4088 patients.
REC name
West of Scotland REC 5
REC reference
20/WS/0077
Date of REC Opinion
21 May 2020
REC opinion
Favourable Opinion